Zacks Investment Research cut shares of Selecta Biosciences (NASDAQ:SELB) from a buy rating to a hold rating in a research report released on Thursday morning.
According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “
SELB has been the subject of several other reports. Janney Montgomery Scott reiterated a buy rating on shares of Selecta Biosciences in a report on Tuesday, October 23rd. BidaskClub downgraded Selecta Biosciences from a buy rating to a hold rating in a report on Friday, October 5th. UBS Group set a $6.00 price target on Selecta Biosciences and gave the company a hold rating in a report on Friday, November 9th. Mizuho reiterated a buy rating and issued a $30.00 price target on shares of Selecta Biosciences in a report on Monday, November 5th. Finally, Stifel Nicolaus started coverage on Selecta Biosciences in a report on Friday, September 14th. They issued a buy rating and a $24.00 price target for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of Hold and an average target price of $23.21.
SELB traded down $0.05 during trading on Thursday, hitting $2.39. The company’s stock had a trading volume of 238,925 shares, compared to its average volume of 362,825. The company has a market capitalization of $59.45 million, a PE ratio of -0.75 and a beta of 2.62. Selecta Biosciences has a twelve month low of $2.28 and a twelve month high of $16.55.
Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.71) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.08. As a group, research analysts anticipate that Selecta Biosciences will post -2.92 earnings per share for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Selecta Biosciences by 1.5% during the 3rd quarter. BlackRock Inc. now owns 897,480 shares of the company’s stock valued at $13,956,000 after buying an additional 12,916 shares during the period. Vanguard Group Inc grew its stake in shares of Selecta Biosciences by 1.1% during the 3rd quarter. Vanguard Group Inc now owns 655,771 shares of the company’s stock valued at $10,197,000 after buying an additional 6,859 shares during the period. Artal Group S.A. grew its stake in shares of Selecta Biosciences by 12.3% during the 3rd quarter. Artal Group S.A. now owns 561,540 shares of the company’s stock valued at $8,732,000 after buying an additional 61,540 shares during the period. Man Group plc grew its stake in shares of Selecta Biosciences by 139.1% during the 3rd quarter. Man Group plc now owns 257,315 shares of the company’s stock valued at $4,001,000 after buying an additional 149,685 shares during the period. Finally, Northern Trust Corp grew its stake in shares of Selecta Biosciences by 11.9% during the 2nd quarter. Northern Trust Corp now owns 156,708 shares of the company’s stock valued at $2,076,000 after buying an additional 16,615 shares during the period. 51.04% of the stock is owned by institutional investors.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.
Recommended Story: SEC Filing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.